Halsoklustret AB
- Address
- lock Available on a paid plan
Nervous System Diseases
The research team at Halsoklustret AB is conducting studies on migraine, exploring both preventive strategies and acute relief options to improve patient quality of life.
- Evaluation of oral CGRP receptor antagonist for migraine prevention
- Acute pain relief assessment in migraine attacks
- Patient‑reported outcome measures for treatment effectiveness
- Response analysis in individuals with prior preventive therapy failure
These investigations aim to test new therapeutic approaches and refine management guidelines for adults experiencing recurrent migraine episodes, with the study site situated in Stockholm, Sweden.
Respiratory Tract Diseases
Clinical research at this Stockholm hospital focuses on asthma and COPD, assessing novel biologic agents and safety profiles to reduce disease burden and exacerbations.
- Pharmacokinetic and immunogenicity profiling of investigational respiratory drugs
- Safety and tolerability evaluation in moderate to severe asthma
- Impact of adjunctive therapy on COPD exacerbation frequency
- Biomarker‑guided patient selection for respiratory trials
The goal of these studies is to improve therapeutic options and long‑term outcomes for patients with chronic respiratory conditions, supported by the expertise of a dedicated investigator team.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1AstraZeneca AB1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 188 other sites in Sweden
Therapeutic Area Benchmark — Sweden
Select a therapeutic area to compare against other sites in Sweden.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Sweden
Market Share
Country: Sweden
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Halsoklustret AB
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (PROSPERO) | AstraZeneca AB | Phase III | Not Recruiting | Apr 2023 | May 2026 |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Rimegepant | 2 | Unknown | 2023-03-14 | 2023-03-14 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.